PHIBRO ANIMAL HEALTH CORPPAHC财报
Nasdaq · 医疗保健 · 药物制剂
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
PAHC 2026财年Q2 Key Financial Metrics
营收
$373.9M
毛利润
$132.7M
营业利润
$50.3M
净利润
$27.5M
毛利率
35.5%
营业利润率
13.5%
净利率
7.3%
同比增长
20.9%
EPS
$0.67
PHIBRO ANIMAL HEALTH CORP 2026财年Q2 财务摘要
PHIBRO ANIMAL HEALTH CORP 2026财年Q2营收 $373.9M（同比增长 20.9%），净利润 $27.5M（同比增长 762.1%）（净利率 7.3%）。销售成本 $241.3M，运营费用 $82.3M。
核心财务指标
| 总营收 | $373.9M |
|---|---|
| 净利润 | $27.5M |
| 毛利率 | 35.5% |
| 营业利润率 | 13.5% |
| 报告期 | 2026财年Q2 |
营收拆解
PHIBRO ANIMAL HEALTH CORP 2026财年Q2营收 $373.9M 共来自 5 个业务板块，最大板块 Medicated Feed Additives And Others 贡献 $202.1M（占 54.1%）。
| 业务分部 | 营收 | 占比 |
|---|---|---|
| Medicated Feed Additives And Others | $202.1M | 54.1% |
| Mineral Nutrition | $68.9M | 18.4% |
| Nutritional Specialties | $50.2M | 13.4% |
| Vaccines | $37.6M | 10.1% |
| Performance Products | $15.0M | 4.0% |
PHIBRO ANIMAL HEALTH CORP 分部营收 — 季度趋势
PHIBRO ANIMAL HEALTH CORP 过去 4 个季度各业务板块营收走势，展示 Medicated Feed Additives And Others和Mineral Nutrition 等业务的变化。
| 业务分部 | 2026财年Q2 | 2026财年Q1 | 2025财年Q4 | 2025财年Q3 |
|---|---|---|---|---|
| Medicated Feed Additives And Others | $202.1M | $195.2M | $206.5M | $181.6M |
| Mineral Nutrition | $68.9M | $63.0M | $64.2M | $66.8M |
| Nutritional Specialties | $50.2M | $48.2M | $47.4M | $43.4M |
| Vaccines | $37.6M | $40.1M | $38.6M | $33.4M |
| Performance Products | $15.0M | $17.4M | $22.1M | $22.7M |
PHIBRO ANIMAL HEALTH CORP 年度营收
PHIBRO ANIMAL HEALTH CORP 历年营收汇总，含各年度总量（例如 2025 年营收为 $1.3B）
PHIBRO ANIMAL HEALTH CORP 季度营收与净利润历史
PHIBRO ANIMAL HEALTH CORP 最近 8 个季度的营收、净利润及同比增速
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| 2026财年Q2 | $373.9M | +20.9% | $27.5M | 7.3% |
| 2026财年Q1 | $363.9M | +39.7% | $26.5M | 7.3% |
| 2025财年Q4 | $378.7M | +38.6% | $17.2M | 4.5% |
| 2025财年Q3 | $347.8M | +32.1% | $20.9M | 6.0% |
| 2025财年Q2 | $309.3M | +23.7% | $3.2M | 1.0% |
| 2025财年Q1 | $260.4M | +12.6% | $7.0M | 2.7% |
| 2024财年Q4 | $273.2M | +7.1% | $752.0K | 0.3% |
| 2024财年Q3 | $263.2M | +7.1% | $8.4M | 3.2% |
利润表
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $263.2M | $273.2M | $260.4M | $309.3M | $347.8M | $378.7M | $363.9M | $373.9M |
| 同比增长 | 7.1% | 7.1% | 12.6% | 23.7% | 32.1% | 38.6% | 39.7% | 20.9% |
资产负债表
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $979.0M | $982.2M | $966.3M | $1.29B | $1.32B | $1.36B | $1.39B | $1.41B |
| 总负债 | $708.9M | $725.5M | $707.8M | $1.04B | $1.05B | $1.08B | $1.07B | $1.07B |
| 股东权益 | $270.1M | $256.6M | $258.5M | $246.8M | $266.0M | $285.7M | $311.7M | $332.4M |
现金流量表
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $11.4M | $28.4M | $12.6M | $3.1M | $43.2M | $21.3M | $9.3M | $19.4M |